Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04997005
Active, not recruiting Observational

The Medacta International AMIStem-P Post-Marketing Surveillance Study

NCT04997005 · tracked via the Priya Life Science France tracker
Sponsor
Medacta International SA
Phase
Observational
Started
2019-04-26
Last updated
2025-05-08

Condition(s) studied

ArthrosisTraumatic ArthritisRheumatoid PolyarthritisCongenital Hip DysplasiaAvascular Necrosis of the Femoral Head

Investigational drug(s) / intervention(s)

AMIStem-P

AMIStem-P: Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant

Study summary

This is a Post-Market Surveillance study of AMIStem-P femoral stem prosthesis

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with a disease (primary coxarthrosis, inflammatory arthritis of the hip, necrosis of the femoral head, etc.) requiring a total hip replacement * Patient eligible to receive an uncemented AMIStem-P femoral stem * Patient agreeing to comply with the study requirements * Patient willing to provide written informed consent * Patient affiliated to a social security system * Patients between 18 and 85 years old Exclusion Criteria: * Participation in biomedical research * Patients younger than 18 years old * Vulnerable adult patients according to article L1121-6 of the French Public Health Code * Pregnant or breastfeeding women * Patients unable to provide written informed consent

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Clinique de Saint Omer Blendecques France
Hôpital Castres Castres France
Nouvelle Clinique Bordeaux Tondu Floirac France
Clinique d'Orange Orange France
Hôpital Jacques-Puel Rodez France

More Medacta International SA trials in France

Bone Fixation of Mpact Double Mobility Cup Active, not recruiting
Multicenter Mpact DM France Recruiting
GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs Active, not recruiting
The Medacta GMK SpheriKA Post-Marketing Surveillance Study Recruiting
Clinical and Radiological Outcomes of Medacta Shoulder System FR Recruiting

Other trials for the same condition

Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology) Recruiting
The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study Active, not recruiting
Persona Partial Knee Clinical Outcomes Study Active, not recruiting
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee Active, not recruiting
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04997005 on ClinicalTrials.gov ↗ ← All trials in France